Pharmacy Focus: Oncology Edition- Latest Updates in Non-Small Cell Lung Cancer Treatment

February 26, 2024

Commentary

Podcast

A brief overview of 4 recent developments in the treatment of non-small cell lung cancer.

This podcast episode provided an oncology news roundup focusing on 4 updates related to non-small cell lung cancer treatment. It discussed the role of pharmacists in chemotherapy management for NSCLC patients and barriers like insurance coverage. It also reviewed two recent FDA drug approvals for advanced NSCLC and results from a phase 3 trial that did not meet its primary endpoint.

Timestamps

[0:00:27-0:01:00] - Pharmacists' involvement among patients with non-small cell lung cancer
[0:01:00-0:02:00] - FDA approval of osimertinib in combination with chemotherapy for EGFR-mutated NSCLC
[0:02:00-0:02:30] - FDA approval of datopotamab deruxtecan for previously treated NSCLC
[0:02:30-0:03:17] - Phase 3 trial of sacituzumab govitecan in metastatic NSCLC that did not meet its primary endpoint

Key Takeaways

Pharmacists play an important role in chemotherapy management for NSCLC patients, but insurance coverage can be a barrier.
Osimertinib in combination with chemotherapy received FDA approval for locally advanced or metastatic EGFR-mutated NSCLC and showed improved progression-free survival.
Datopotamab deruxtecan received FDA approval for previously treated locally advanced or metastatic non-squamous NSCLC.
A phase 3 trial of sacituzumab govitecan failed to meet its primary endpoint of improved overall survival in metastatic NSCLC, though some benefit was seen in squamous and non-squamous subgroups.